Publications in collaboration with researchers from New York University Langone Medical Center (15)

2024

  1. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 187, pp. 128-138

  2. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

2023

  1. Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

    International Journal of Gynecological Cancer, Vol. 33, Núm. 11, pp. 1733-1742

  2. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

    European Journal of Cancer, Vol. 189

2022

  1. PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy

    Clinical Cancer Research, Vol. 28, Núm. 15, pp. 3182-3184

  2. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

    Journal of Clinical Oncology, Vol. 39, Núm. 24, pp. 2656-2666

  2. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027

2020

  1. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

    Nature, Vol. 583, Núm. 7817, pp. 609-614

  2. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

  3. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer

    Gynecologic Oncology, Vol. 159, Núm. 2, pp. 322-328

2019

  1. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis

    Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673

  2. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402

2017

  1. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 389, Núm. 10064, pp. 67-76

2016

  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920